Alzinova

Alzinova AB is a Swedish biopharmaceutical company focused on developing treatments for Alzheimer’s disease. Its core programs are the therapeutic vaccine ALZ-101 and the monoclonal antibody ALZ-201, both built on the company’s proprietary scientific platform.

— Alzinova
	%
Therapeutic vaccine	50% ALZ-101 is a vaccine candidate designed for the treatment of Alzheimer’s disease.
Monoclonal antibody	20% ALZ-201 is an antibody program intended as a complementary Alzheimer’s treatment.
Clinical development pipeline	20% Internal R&D activities that advance the company’s drug candidates through studies.
Partnering and outlicensing	10% Business development activities aimed at licensing candidates to pharma partners.

Alzinova does not sell commercial medicines today; its direct counterparties are pharmaceutical companies, potential...

Pharmaceutical partnering companiesprimary
They buy rights to ALZ-101 or ALZ-201 through outlicensing or acquisition because they have the scale to run late-stage development and commercialization.
Clinical research organizationssecondary
They provide trial execution, regulatory support, and study operations needed to advance the pipeline.
Manufacturing and supply partnerssecondary
They produce drug substance and drug product for preclinical and clinical use.
Institutional investors and financing partnersprimary
They fund the company through equity and other capital raises that support development work.

Alzinova is headquartered in Sweden and reports in SEK, with operations centered on Swedish corporate and development...

•Sweden is the corporate base and reporting currency is SEK
•Clinical and regulatory work is organized for global development
•U.S. regulatory status supports partnering discussions
•Europe is relevant for scientific and regulatory engagement
•Saudi Arabia is mentioned as a collaboration market

Alzinova’s strategy is to advance ALZ-101 through clinical proof-of-concept while building partnering optionality with...

Advance ALZ-101 into Phase IIshort-term

Clinical proof-of-concept is central to validating the lead asset and increasing partnering value.

Secure strategic partnershipsshort-term

A larger partner can fund late-stage development, registration, and commercialization.

Build a complementary pipeline around ALZ-201medium-term

A second asset can broaden the platform and create additional partnering options.

Alzinova’s business depends on clinical success, regulatory acceptance, and the ability to finance long development...

high

Clinical development failure

ALZ-101 must show acceptable efficacy and safety in later-stage studies to justify continuation and partnering.

Scope: ALZ-101 Phase II and ALZ-201 development
Materiality: high

high

Liquidity and financing dependence

The company has no commercial product revenue and relies on external capital to fund R&D and trials.

Scope: Equity issues, grants, and other financing
Materiality: high

medium

Supplier and manufacturer dependence

Critical development work is outsourced and quality failures could delay studies or regulatory readiness.

Scope: Drug substance, drug product, and CRO partners
Materiality: medium

medium

Key-person and recruitment risk

A small organization makes the company sensitive to loss of specialized scientific and regulatory staff.

Scope: Clinical, regulatory, and business development functions
Materiality: medium

Capitalized development costs

Reported expenses and balance sheet intangible assets

Clinical study and regulatory cost timing

Quarter-to-quarter comparability

Equity financing and warrants

EPS, dilution, and cash runway

Going-concern judgment

Financial statement disclosures and investor interpretation

Alzinova

Clinical development failure

Liquidity and financing dependence

Supplier and manufacturer dependence

Key-person and recruitment risk

Alpha Teknova, Inc.

Innoviva, Inc.

LENZ Therapeutics, Inc.

BIOMARIN PHARMACEUTICAL INC

ALTRIA GROUP, INC.

Serina Therapeutics, Inc.